| Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | British Journal of Dermatology | ||||
| Publisher: | OXFORD UNIV PRESS | ||||
| Place of Publication: | OXFORD | ||||
| Date: | 2023 | ||||
| Institutions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number: |
| ||||
| Keywords: | BREAST-CANCER; BCL-2; AMPLIFICATION; NAVITOCLAX; EXPRESSION; PHASE-2; | ||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Yes | ||||
| Item ID: | 76022 |
Web of ScienceAbstract
Immunotherapies are effective in the treatment of patients with Merkel cell carcinoma (MCC), but for patients whose tumour cannot be controlled by the immune system, alternative approaches are urgently needed. To this end, overexpressed oncogenes may represent potential drug targets. We show that antiapoptotic protein B-cell lymphoma-extra large (Bcl-xL) is highly expressed by MCC cells and is ...
Abstract
Immunotherapies are effective in the treatment of patients with Merkel cell carcinoma (MCC), but for patients whose tumour cannot be controlled by the immune system, alternative approaches are urgently needed. To this end, overexpressed oncogenes may represent potential drug targets. We show that antiapoptotic protein B-cell lymphoma-extra large (Bcl-xL) is highly expressed by MCC cells and is therefore an attractive therapeutic target, especially as we also demonstrate that the effect of specific Bcl-xL inhibitors is synergistically enhanced by concurrent PARP inhibition. Background Merkel cell carcinoma (MCC) is an aggressive skin tumour with neuroendocrine differentiation. Immunotherapies are effective in the treatment of patients with advanced-stage MCC, but for patients whose tumours cannot be controlled by the immune system, alternative approaches are urgently needed. Objectives To identify overexpressed oncogenes as potential drug targets for MCC. Methods NanoString platform, digital droplet polymerase chain reaction (ddPCR) and fluorescence in situ hybridization (FISH) assays were used to determine copy number variations (CNVs); BCL2L1 and PARP1 mRNA expression levels were determined by quantitative real-time polymerase chain reaction (qRT-PCR), B-cell lymphoma extra-large (Bcl-xL) and poly (ADP-ribose) polymerase 1 (PARP1) protein by immuno-blot. Specific Bcl-xL inhibitors and a PARP1 inhibitor were used alone or in combination to test their antitumour effect. Results Screening for CNVs in 13 classic Merkel cell polyomavirus (MCPyV)-positive and MCPyV-negative MCC cell lines revealed BCL2L1 gains and amplifications, confirmed by ddPCR in 10 cell lines. By ddPCR and FISH, we demonstrated that BCL2L1 gains are present in tumour tissue. BCL2L1 copy number gains were associated with increased Bcl-xL mRNA and protein expression. However, high Bcl-xL expression was not restricted to MCC cells harbouring a BCL2L1 gain/amplification, suggesting additional epigenetic means of regulation. The functional relevance of Bcl-xL in MCC cells was demonstrated by the fact that specific Bcl-xL inhibitors (A1331852 and WEHI-539) led to the induction of apoptosis. Owing to the strong expression and activation of PARP1 in MCC cell lines, we next tested the combination of Bcl-xL inhibitors with the PARP1 inhibitor olaparib, which showed synergistic antitumour effects. Conclusions Bcl-xL, which is highly expressed in MCC, appears to be an attractive therapeutic target for the treatment of this tumour, especially as the effect of specific Bcl-xL inhibitors is synergistically enhanced by simultaneous PARP inhibition.
Metadata last modified: 18 Mar 2025 10:08
Altmetric